Design Therapeutics Inc (NASDAQ: DSGN) on Friday, soared 10.04% from the previous trading day, before settling in for the closing price of $6.87. Within the past 52 weeks, DSGN’s price has moved between $2.60 and $7.77.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -88.52%. The company achieved an average annual earnings per share of -30.30%. With a float of $31.12 million, this company’s outstanding shares have now reached $56.96 million.
Design Therapeutics Inc (DSGN) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Design Therapeutics Inc is 45.37%, while institutional ownership is 45.61%. The most recent insider transaction that took place on Nov 07 ’25, was worth 2,851,050. Before that another transaction happened on Aug 13 ’25, when Company’s Director sold 562,627 for $5.25, making the entire transaction worth $2,953,792. This insider now owns 1,000,000 shares in total.
Design Therapeutics Inc (DSGN) Latest Financial update
As on 12/31/2024, Multinational firm has announced its last quarter scores, in which it reported -0.24 earnings per share (EPS) for the period topping the consensus outlook (set at -0.27) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.32 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -30.30% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -17.02% during the next five years compared to -88.52% drop over the previous five years of trading.
Design Therapeutics Inc (NASDAQ: DSGN) Trading Performance Indicators
Design Therapeutics Inc (DSGN) is currently performing well based on its current performance indicators. A quick ratio of 18.71 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.19, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach -1.26 in one year’s time.
Technical Analysis of Design Therapeutics Inc (DSGN)
The latest stats from [Design Therapeutics Inc, DSGN] show that its last 5-days average volume of 0.34 million was superior to 0.15 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 75.75%.
During the past 100 days, Design Therapeutics Inc’s (DSGN) raw stochastic average was set at 91.96%, which indicates a significant increase from 86.04% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.53 in the past 14 days, which was higher than the 0.41 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.32, while its 200-day Moving Average is $4.73. Now, the first resistance to watch is $8.06. This is followed by the second major resistance level at $8.56. The third major resistance level sits at $9.19. If the price goes on to break the first support level at $6.93, it is likely to go to the next support level at $6.30. The third support level lies at $5.80 if the price breaches the second support level.
Design Therapeutics Inc (NASDAQ: DSGN) Key Stats
Market capitalization of the company is 430.65 million based on 56,964K outstanding shares. Right now, sales total 0 K and income totals -49,590 K. The company made 0 K in profit during its latest quarter, and -19,080 K in sales during its previous quarter.
